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Introduction
The meeting was attended by approximately 80 people
and was designed to bring together an international
group of academic investigators and industrial scientists
in a forum that would foster discussion and exchange of
ideas. The purpose of the meeting was to assess current
animal models of emphysema and COPD, and to
promote the use of new technologies. The immediate
goal was to accelerate the translation of information
gained from the development of animal models to
improvements in patient care. Specifically, the formal
presentations and informal discussions held during the
conference addressed aetiological factors in COPD, and
emphasized transgenic technologies and naturally occur-
ring genetic variants. The objectives of the programme
were to consolidate our present understanding of lung
and airway inflammation, and its involvement in the
pathogenesis of COPD caused by cigarette smoking,
ageing and genetic predisposition; and to promote
further imaginative investigations.
Lung physiology and lung function
Dr A. Ten Have-Opbroek (Leiden University, Leiden, The
Netherlands) presented an overview of lung development,
stating that animal models may contribute to our insight
into the pathogenesis of human COPD because there are
major similarities in lung development and lung structure
between mammals. Many attendees presented data at the
meeting on the pathogenesis of emphysema/COPD,
whereas little was presented regarding function of the
lungs. The use of pathology to establish the presence of
disease allied to an assessment of lung mechanics may
provide a more meaningful assessment in the animal
model of choice.
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Abstract
The meeting proved of great interest to those developing an animal model of chronic obstructive
pulmonary disease (COPD). COPD is caused by cigarette smoking, evidenced by deterioration in lung
function. Lung function is only rarely assessed in animal models. A cigarette smoke driven pathology
should provide the best in vivo model for COPD. However, as lesions produced this way take
8–12 months to develop other strategies have to be employed. Emphysematous lesions were also
achieved by treatment with elastase, lipopolysaccharide, ozone and other inducers. Several studies
described treatments that have shown activity in these models. Transgenic models were discussed, as
was the importance of species and strain selection.
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Dr M. Rubio (Fundacion de Jimenez Diaz, Madrid, Spain)
presented work in the rat. Intratracheal instillation of
cadmium chloride was used to induce lung fibrosis, and
instillation of elastase was used to generate an emphysema-
tous pathology. Forty-five days after instillation lung function
was assessed and significant changes were demonstrated
with both treatments, effects that could be reversed by oral
administration of the antioxidant N-acetylcysteine. This
clearly demonstrates that emphysema-induced changes in
lung function can be demonstrated in the rat, and informal
discussions at the meeting revealed that work is underway
to develop equipment to allow similar measurements in the
mouse. This will be a significant step forward in the assess-
ment of these models, not least because many groups are
using the mouse as their animal of choice. As mentioned
below, Dr. P. Belloni (Roche Bioscience, Palo Alto, Califor-
nia, USA) also measured changes in lung function after
elastase treatment in the rat.
Smoking models
Dr J. Wright (University of British Columbia, Vancouver,
British Columbia, Canada) provided an overview of ciga-
rette-smoke-induced models, highlighting the time needed
to produce lesions (up to 12 months in some species) and
the importance of the choice of animal and strain. Of
people who smoke 15–20% develop COPD, and the
lesions produced in these models are similar to those
observed in humans.
Dr C. Hobbs (Lovelace Respiratory Research Institute,  Albu-
querque, New Mexico, USA) outlined a study in which the
responses to chronic exposure to cigarette smoke in the rat
and mouse were compared. That work revealed a greater
inflammatory and emphysematous response in the B6C3F1
mouse than in the F344 rat. These changes were seen in the
mouse after 7 and 13 months of exposure to cigarette
smoke for 6 h/day, 5 days/week, and were progressive.
A poster from Dr M. Fitzgerald (Bayer, Stoke Poges, UK)
described the effect of BAY 15-7496, a potent inhibitor of
matrix metalloproteinases, on cigarette smoke exposure in
mice. Short-term exposure to cigarette smoke for 4 or
20 min elicited an acute inflammatory response. Interest-
ingly, an analysis of the cells involved showed only
macrophage and epithelial cells, with no neutrophil influx
evident. After long-term exposure to cigarette smoke
(6 days/week for 14 or 26 weeks), a significant degree of
emphysema developed. Treatment with BAY 15-7496
(10 mg/kg twice a day) throughout exposure to cigarette
smoke almost completely abolished the emphysematous
response, thus supporting a role for matrix metallopro-
teinases in the development of cigarette-smoke-induced
emphysema.
Dr J. Hogg (McDonald Research Laboratory, Vancouver,
Canada) presented data demonstrating that latent aden-
ovirus infection enhances the emphysematous destruction
of lung in guinea pigs after exposure to cigarette smoke.
An interesting observation was that both exposure to ciga-
rette smoke and adenovirus infection increased levels of
neutrophils and alveolar macrophages, whereas only the
former increased CD4+ lymphocytes and only the latter
increased CD8+ lymphocytes. Also of interest was that,
contrary to other studies [1], retinoic acid had no effect on
the inflammatory response or the emphysematous
changes observed in that study. However, Dr P. Belloni
(Roche Bioscience) presented data suggesting that
retinoids selective for the retinoic acid receptor-γ or
retinoic acid analogues (e.g. all-trans retinoic acid) are
necessary to promote alveolar repair by inducing anabolic
pathways similar to those activated in late-stage lung
development. By measuring lung function in an elastase-
induced model of emphysema in the rat Dr Belloni demon-
strated an increase in lung resistance and capacity after
elastase treatment. This increase was partly reversed by
retinoid treatment, but reversals of elastase-induced
changes in forced expiratory volume/forced vital capacity
or forced expiratory flow25–75 were not seen.
Dr Tralau-Stewart (GlaxoSmithKline, Stevenage, UK)
described work in a 3-day model of cigarette smoke expo-
sure in mice in which cigarette-smoke-induced neu-
trophilia was inhibited by pretreatment with the p38 kinase
inhibitor SB 239063.
Other models
Smoking accounts for 85–90% of cases of COPD in
humans and, although a cigarette-smoke-driven model
would be desirable, Dr Tralau-Stewart (GSK) also dis-
cussed a variety of other animal models and outlined the
approaches necessary to develop drugs for the treatment
of COPD. Mechanistic models that mimic certain aspects
of the disease are widely used in drug development to
identify and optimize candidate compounds. Models that
employ ozone, lipopolysaccharide, sulphur dioxide, nitro-
gen dioxide and diesel particles have all been used to
produce aspects of COPD such as cough, inflammation
and mucus hypersecretion. Elastase has been used in a
variety of species. Dr Tralau-Stewart and coworkers have
demonstrated inhibition in an ozone-induced model of
COPD with the p38 kinase inhibitor SB 239063; inhibi-
tion of neutrophilia in an lipopolysaccharide-driven model
with GW 311616, an elastase inhibitor; and, in a multi-
dose lipopolysaccharide model, they demonstrated effi-
cacy of the steroid, fluticasone. Dr Tralau-Stewart
stressed the need to look for improved methodologies and
protocols, and end-points other than pathology with bio-
markers and lung function being the desired goal.
Transgenic models
Several authors presented work with different transgenic
mice. Dr P. Martorana (Siena University, Siena, Italy)
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the pallid mouse, an animal that has reduced elastase
inhibitory capacity. Development of emphysema is slow,
taking 8–12 months, but can be accelerated by treatment
with formyl-methionyl-leucyl phenylalanine or exposure to
cigarette smoke. Dr Suga (Gunma University, Japan)
described work with the Klotho mouse, which develops air-
space enlargement early in life. However, there was some
discussion as to whether this was due to alveolar destruc-
tion or a lack of septation with development. The same
argument could be levelled at transgenic mice expressing
transforming growth factor-α, a model described by Dr W.
Hardie (Children’s Hospital Medical Center, Cincinnati,
OH, USA). However, in this model Dr Hardie and cowork-
ers confirmed the importance of the gene by conditional
expression in adulthood, which resulted in the development
of significant alveolar emphysema.
Strain variations
Dr B. Bartalesi (Siena University, Siena, Italy) described a
study employing several strains of mice in which neu-
trophil influx into the airways was induced by formyl-
methionyl-leucyl phenylalanine instillation. This influx
resulted in the development of significant emphysema in
pallid mice and C57Bl/6J mice; both of these strains have
a lower serum elastase inhibitory capacity, unlike the
NMRI mouse, which has higher elastase inhibitory capac-
ity and which did not develop emphysema. The degree of
lung destruction correlated inversely with the elastase
inhibitory capacity. It was therefore suggested that treat-
ments that induce neutrophil influx into the lungs would
only result in emphysema in animals with reduced elastase
inhibitory capacity, an important consideration when devel-
oping a model of emphysema.
In a poster (outlined above), Dr M. Fitzgerald (Bayer)
examined the effects of cigarette smoke exposure in two
different strains of mice. Dr Fitzgerald suggested that,
after long-term exposure, a faster development of emphy-
sema (in approximately half the time) occurred in A/J mice
when compared with C57Bl/6J mice. Those data also
suggested a greater inflammatory response in the A/J
mice after short-term exposure to cigarette smoke.
Dr G. Lungarella (Siena University, Siena, Italy) also
stressed the importance of strain selection and stated that
it is important to determine the antiprotease and antioxi-
dant status of the chosen model. That investigator showed
that C57Bl/6J and DBA/2J mice (reduced antielastase
and increased sensitivity to oxidants) were more respon-
sive to cigarette smoke exposure than were ICR mice
(normal antielastase and lack of sensitivity to oxidants).
Conclusion
It was evident from this meeting that a great deal of effort
is going on worldwide to produce animal models of COPD
that are both predictive of the human condition and user-
friendly to the experimentalist. Animal models that may be
of great benefit to the study of the mechanisms involved in
the development of COPD were described. The impor-
tance of animal and strain selection was stressed and the
need to use cigarette smoke as a stimulus wherever possi-
ble was also highlighted, whereas other possible
approaches to the induction of emphysema were also
described. It was evident from the meeting that much
more needs to be done in this field and that the impor-
tance of having robust animal models of the disease that
are generally available is paramount. In conclusion, the
meeting was very successful and provided plenty of food
for thought for both the academic and industrial scientists.
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